论文部分内容阅读
加《医学邮报》第15卷第13期(1979年6月19日)报道:加拿大对于一种价廉而能大量生产的生物活性聚合物试验的结果表明,这种聚合物能把免有疫反应的B细胞转变为强大的杀癌剂。以NED137为研究代号的生物聚合物,已完成动物试验及Ⅰ期临床试验,即将开始Ⅱ期临床试验。多伦多综合医院戈尔迪·罗特曼肿瘤科的福尔克(Rudy Falk)医生及其小组,正在研究此种聚合物的抗肿瘤作用。他对此聚合物的效能印象深刻,特别是此聚合物完全没有毒性。象NED137这样对肿瘤有杀伤力的抗癌剂,对试验动物没有毒性,确为罕见。
Plus, Medical Post, Vol. 15, No. 13 (June 19, 1979) reports: Canada’s results for a low-cost, high-volume bioactive polymer test show that the polymer can be dispensed with The B-cells in the epidemic reaction turned into powerful anti-cancer agents. The biological polymers based on NED137 as the study code have completed animal experiments and Phase I clinical trials. Phase II clinical trials are about to begin. Dr. Rudy Falk of the Department of Oncology of the General Hospital of Toronto General Hospital and his team are studying the anti-tumor effects of this polymer. He is very impressed with the performance of this polymer, in particular the polymer is completely non-toxic. Anti-cancer agents such as NED137 that are lethal to tumors have no toxicity to experimental animals and are rare.